Microarray expression profiling of long noncoding RNAs in the progesterone-treated lung cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Lung cancer incidence and unique biological features in women are increasing.
• Sex hormones, particularly progesterone (P4), are implicated in lung cancer.
• Previous research demonstrated P4's inhibitory effect on lung cancer tumorigenesis and progression.

Purpose of the Study:

• To investigate the effects of progesterone (P4) on the expression of long noncoding RNAs (lncRNAs) and their target messenger RNAs (mRNAs) in lung cancer cells.
• To identify novel lncRNAs and mRNAs regulated by P4 in lung cancer.
• To explore the potential of lncRNAs as therapeutic targets in P4-sensitive lung cancer.

Main Methods:

• High-throughput microarray analysis was employed to identify differentially expressed lncRNAs and mRNAs.
• Bioinformatics analysis, including gene ontology, pathway, and network analyses, was performed.
• Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to validate the differential expression of a lncRNA signature.

Main Results:

• Progesterone treatment significantly altered the expression of 692 lncRNAs and 268 mRNAs in A549 human lung cancer cells.
• Of the differentially expressed lncRNAs, 82 were up-regulated and 610 were down-regulated.
• Pathway analysis indicated that differentially expressed mRNAs are involved in key regulatory pathways, including Notch signaling.

Conclusions:

• This study is the first to report differentially expressed lncRNAs in progesterone-treated lung cancer cells.
• The identified lncRNAs represent potential therapeutic targets for progesterone-sensitive lung cancer.
• lncRNAs play a significant role in the biological effects of progesterone on lung cancer.